Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer sticks to bone...

    Bayer sticks to bone metastasis drug estimate after setback

    Written by Ruby Khatun Khatun Published On 2017-12-06T09:15:50+05:30  |  Updated On 17 Aug 2021 11:42 AM IST

    BERLIN: Bayer is sticking to its peak sales estimate for bone metastasis drug Xofigo despite a setback in a late-stage drug trial, the head of the German group's pharmaceuticals unit said on Friday.


    In a trial, which was designed to widen the use of radiology drug Xofigo among prostate cancer patients with painful bone metastases, more cases of bone fractures and deaths occurred than in the control group on placebo, according to a statement from Bayer released late on Thursday.


    The study, intended to bring the drug to bone metastasis patients at an earlier stage of treatment, was then unblinded in the interest of patient safety, meaning participants and doctors were told who received Xofigo and who was part of the control group on ineffective placebo.


    Asked whether Bayer's sales estimate for Xofigo of at least 1 billion euros ($1.2 billion) would have to be lowered, Bayer's head of pharmaceuticals Dieter Weinand said: "We have not revised our peak sales estimate."


    The company, holding a media event in Berlin on Friday, also reaffirmed that the drug would continue to be tested on other tumour types such as breast cancer and types of blood cancer. ($1 = 0.8413 euros)


    (Writing by Ludwig Burger; Editing by Adrian Croft)

    Bayerbone metastasis drugdoctorspharma newsPharmaceuticalsprostate cancerradiologyXofigo
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok